Graham Parry
Chief Scientific OfficerDr. Graham Parry, Ph.D., is Chief Scientific Officer of Electra Therapeutics, Inc. from December 2023. He was Executive Vice President of Translational Sciences at Star Therapeutics. He worked cross-functionally with scientists, clinicians and executive leadership at Star to advance the development of novel treatments for rare diseases. He has experience and enthusiasm to the development of novel therapies for rare and life-threatening diseases. Prior to joining Star, he served as Senior Vice President of Translational Sciences at Third Harmonic Bio, where he worked to advance treatments for allergic and inflammatory diseases. Graham was also VP of Technical Operations at True North Therapeutics and worked closely with several Star team Members on the discovery and development of ENJAYMO, a first-in-class inhibitor of the classical complement pathway that achieved FDA Breakthrough Therapy Designation and approval for cold agglutinin disease. He has been Vice President of Technical Operations Bioverativ USA Inc. since December 26, 2016. Dr. Parry served as Senior Director of Translational Research of Bioverativ USA Inc. until December 26, 2016 and also served as its Senior Director of Translational Research. Dr. Parry joined Bioverativ USA Inc. in March 2012. He has experience in drug discovery and pre-clinical development in the biotech industry. Previously, he was Director of Biology at Attenuon LLC, where he was involved in the development of two drugs that entered Phase II clinical trials and where he discovered an antibody targeting the urokinase receptor (uPAR) with robust anti-tumor activity. Dr. Parry has worked with San Diego based Motility Inc. and directed the preclinical development of a novel biotherapeutic with applications in oncology and ophthalmology. Dr. Parry has published 45 original articles in refereed journals, several book chapters and reviews. Dr. Parry obtained a bachelor’s of science degree in Applied Biology at Brunel University and a Ph. D. in Biochemistry from the University of London. His postdoctoral research was conducted at The Scripps Research Institute and focused on the regulation of endothelial cell gene expression, coagulation and fibrinolysis.
Positions
- Company NameElectra Therapeutics, Inc.Stock CodeETRAPositionChief Scientific Officer
